Black Diamond Therapeutics, Inc.

Ownership Transactions Reported by 20 Insiders

Symbol
BDTX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
One Main Street, 14 Th Floor, Cambridge, Massachusetts

Insiders trading volume in the past year

Black Diamond Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Biotech Growth N V 10%+ Owner $23.3 M +$934 K +4.19% Oct 17, 2023
Ali Behbahani Director $22.4 M Jun 21, 2024
Ra Capital Management, L.P. Director $8.77 M Jul 5, 2023
David M. Epstein Officer Title: President and Chief Executive Officer, Director $1.88 M Jun 27, 2023
Wendy L. Dixon Director $173 K Mar 15, 2024
Mark A. Velleca PRESIDENT & CEO, Director $127 K Feb 14, 2024
Robert Alexander Ingram Former Director $117 K Dec 16, 2022
Erika Jones Officer Title: Vice President, Finance and Corporate Controller $27.7 K Feb 14, 2024
Prakash Raman Director $11.5 K Jun 21, 2024
Shannon Campbell Director $10 K Jun 21, 2024
Bradley J. Bolzon PhD Director, 10%+ Owner Jun 18, 2021
Elizabeth Buck Chief Scientific Officer Feb 14, 2024
E. Garry Menzel Director Jun 6, 2024
Alexander Mayweg Director May 16, 2023
Fang Ni Officer Title: Chief Business Officer and Chief Financial Officer Feb 14, 2024
Samarth Kulkarni Director Jun 6, 2024
Brent Hatzis-Schoch Officer Title: Chief Operating Officer and General Counsel Feb 14, 2024
Kapil Dhingra Director Jun 6, 2024
Rajeev M. Shah Director May 16, 2023
Sergey Yurasov Chief Medical Officer Feb 14, 2024

Recent Insider Transactions by Companies or Individuals for Black Diamond Therapeutics, Inc.

Insider Class Transaction % Value $ Price $ Shares Shares Owned Date Ownership